<DOC>
	<DOC>NCT00536497</DOC>
	<brief_summary>GW842166X is a selective non-cannabinoid CB2 receptor agonist, which is undergoing clinical development as a novel oral treatment for inflammatory pain. The purpose of the study is to compare the effects of formulation, food and particle size on the pharmacokinetic profiles of a single 175mg dose of GW842166X in healthy male and female volunteers.</brief_summary>
	<brief_title>Relative Bioavailability Study on a Single Dose of GW842166X in Healthy Male and Female Subjects.</brief_title>
	<detailed_description />
	<criteria>Body weight &gt;50 Kg and BMI within the range 18.529.9 Kg/m2 inclusive. Healthy as judged by a responsible physician. Positive prestudy urine screen for drugs of abuse or alcohol breath test.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>GW842166,</keyword>
	<keyword>Healthy volunteers,</keyword>
	<keyword>Inflammatory Pain.</keyword>
</DOC>